Cointime

De Novo Pharmaceuticals

company

About

De Novo Pharmaceuticals is an emerging computational drug design company.

  • 11 - 50

Highlights

Total Funding Amount
£18.75M
Funding Rounds
2
Investors
3

Details

Last Funding Type
Series B
Last Funding Money Raised
£16.75M
Industries
Health Care,Life Science,Medical,Pharmaceutical
Founded date
Jan 1, 1999
Number Of Employee
11 - 50
Operating Status
Active

De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
£18.75M
De Novo Pharmaceuticals has raised a total of £18.75M in funding over 2 rounds. Their latest funding was raised on Jul 26, 2001 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 26, 2001 Series B £16.75M 3 — — Detail
Apr 18, 2000 Series A £2M 1 Prelude Trust — Detail

Investors

Number of Lead Investors
Number of Investors
1
3
De Novo Pharmaceuticals is funded by 3 investors. Prelude Trust and FNI Venture Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Prelude Trust — Series B
FNI Venture Capital — Series B
The Cambridge Gateway Fund — Series B
Cointime
เนื้อหา
บริษัท